サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1795311

ファージ療法の世界市場

Phage Therapy

出版日
ページ情報
英文 149 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.92円
ファージ療法の世界市場
出版日: 2025年08月21日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 149 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ファージ療法の世界市場は2030年までに1億2,480万米ドルに達する見込み

2024年に4,530万米ドルと推定されるファージ療法の世界市場は、2030年には1億2,480万米ドルに達し、分析期間2024～2030年のCAGRは18.4%で成長すると予測されます。本レポートで分析したセグメントの1つである大腸菌は、CAGR 20.4%を記録し、分析期間終了時には6,910万米ドルに達すると予測されます。黄色ブドウ球菌セグメントの成長率は、分析期間中CAGR 15.9％と推定されます。

米国市場は1,190万米ドルと推定、中国はCAGR 17.3％で成長すると予測

米国のファージ療法市場は、2024年には1,190万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGR17.3%で推移し、2030年には予測市場規模1,910万米ドルに達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ17.2％と15.7％と予測されています。欧州では、ドイツがCAGR約13.3%で成長すると予測されています。

世界のファージ療法市場- 主要動向と促進要因のまとめ

バクテリオファージは抗生物質耐性との闘いに新たなフロンティアを提供できるか？

抗生物質耐性の世界的危機の深刻化により、ファージ療法は多剤耐性細菌感染と闘うための有望な選択肢として脚光を浴びています。バクテリオファージ（ファージ）は、細菌に選択的に感染して破壊するウイルスであり、有益な微生物相を乱すことなく、高度に的を絞ったアプローチを提供します。広域スペクトルメカニズムで作用する従来の抗生物質とは異なり、ファージは特定の細菌株を攻撃するように調整することができるため、巻き添え被害を最小限に抑え、耐性菌開発のリスクを低減することができます。抗生物質耐性のスーパーバグが世界的に公衆衛生を脅かし続ける中、ファージ療法の魅力は臨床医学だけでなく、農業、養殖業、食品安全などの分野でも高まっています。複数の国が現在、特に従来の抗生物質が効かないようなケースにおいて、ファージに基づく治療法の研究と臨床統合を促進するための規制経路を再検討しています。特に、同情的な使用事例や個別化された使用事例が、重篤な患者において救命効果を示し、この技術への関心をさらに高めています。学術機関、バイオテクノロジー新興企業、公衆衛生機関は、ファージカクテルの利用可能性とカスタマイズ性を高めるために、世界のファージバンクとシーケンスライブラリーに関する共同研究をますます進めています。ファージと宿主の相互作用の特異性は、課題ではあるが、より広範な生態系への予期せぬ影響を最小限に抑えるという大きな利点もあります。ポスト抗生物質時代における新たなハードルに直面する感染症対策において、ファージ療法は実験的な異常値としてではなく、将来の抗菌プロトコルの戦略的支柱として再評価されています。

バイオテクノロジーの革新は、ファージ療法の臨床的有用性をどのように前進させているのでしょうか？

遺伝子工学、合成生物学、バイオインフォマティクスの進歩は、ファージ療法の臨床的有用性を拡大する上で極めて重要な役割を果たしています。今日のファージ研究は数十年前とは比べものにならないほど洗練されており、細菌防御を克服し、溶菌効率を高め、免疫システムの検出を回避するようにファージを改変することができるようになっています。CRISPR-Casシステムは、特定の耐性遺伝子を標的とすることができるプログラム可能なファージを設計するために使用されており、治療法を幅広い感染症に適応できるものにしています。さらに、シーケンス技術とメタゲノミクスの革新により、効果的なファージと細菌のペアの同定が加速され、個別化治療計画に必要な時間が大幅に短縮されています。また、ファージの安定性、生物学的利用能、感染組織への標的送達を改善するために、カプセル化技術やナノ製剤も登場しています。複数のファージ株を組み合わせたファージカクテルの開発により、スペクトルのカバー率が向上し、治療中の耐性発現が緩和されつつあります。バイオテクノロジー企業は、GMP基準を満たすスケーラブルな生産・精製方法に取り組んでおり、ファージ療法を市場に投入する際の大きなハードルのひとつに取り組んでいます。欧州、北米、アジアでは、慢性創傷から嚢胞性線維症関連病原体に至るまで、感染症治療におけるファージ療法の役割に関する臨床試験がますます盛んになっています。このような技術の勢いは、ファージ療法を最後の砦的な選択肢から、多用途で科学的に検証された治療法へと変えつつあります。ハイスループットなラボツールとAIを駆使したスクリーニングシステムの継続的な融合により、ファージを用いた治療薬は精密医療における次世代の武器として信頼性を増しています。

普及のために解決すべき規制とインフラの課題とは？

その可能性にもかかわらず、ファージ療法の広範な採用は、早急な対応が必要な数多くの規制やインフラの障壁に直面しています。従来の医薬品承認の枠組みは、患者固有の細菌感染に適合させなければならないファージ製剤のような、高度な個別化が必要な治療には適していないです。このような規制の明確性の欠如は臨床開発を遅らせ、大規模な投資を妨げます。FDAやEMAのような規制機関は、思いやりのある使用や病院での免除を含む適応的ライセンシングモデルを徐々に模索しているが、統一された世界の基準はまだ見つかっていないです。これらの生物製剤は、汚染物質がなく、遺伝的に安定で、機能的に再現可能でなければならないため、製造の一貫性、品質管理、ファージ特性はさらなる課題となっています。もう一つのハードルは、医療グレードの基準を満たす商業規模のファージ生産施設の不足にあります。多くの研究機関は、いまだに社内ラボや学術的なセットアップに頼っており、生産量や品質の標準化に限界があります。さらに、ファージ療法の訓練を受けた臨床専門家が少ないことも、病院での日常的な採用を妨げています。一般の人々の認識や意識も科学の進歩に遅れをとっており、多くの人々がファージ療法を実験的あるいは型破りなものとして捉えています。自然界に存在するファージは特許を取得するのが難しいため、知的財産の制約が商業化をさらに複雑にし、民間セクターの投資意欲を減退させています。国境を越えた協力関係や世界・コンソーシアムは、こうしたギャップに対処し始めているが、専用政策、インフラのアップグレード、業界全体の教育の必要性は依然として重要です。医療ツールの主流としてファージ療法の世界の可能性を十分に引き出すには、こうした規制や物流のハードルを克服することが不可欠です。

市場成長の原動力と治療用途の拡大とは？

ファージ療法市場の成長は、技術の進歩、アンメット・クリニカル・ニーズ、進化する患者ケアモデルに関連するいくつかの要因によってもたらされます。最も重要な要因の一つは、多剤耐性感染症の急増であり、従来の抗生物質がますます効かなくなり、実行可能な代替薬への需要が高まっています。同時に、ゲノムおよびプロテオミクスツールの進歩により、ファージの同定、カスタマイズ、配備が劇的に改善され、開発期間が短縮され、治療効果が高まっています。また、慢性感染症や院内感染症の増加も、従来の耐性メカニズムを回避できる標的抗菌薬への需要に拍車をかけています。エンドユーザー側では、病院や感染症専門クリニックが、パイロットプログラムやケーススタディから得られたエビデンスの増加に支えられ、治療が困難な症例に対してファージ療法を取り入れ始めています。バイオ製薬会社や学術研究センターは、ファージライブラリー、予測モデリングソフトウェア、スケーラブルな製造システムの構築に多額の投資を行い、治療法の普及に努めています。抗生物質耐性との闘いに焦点を当てた政府や非営利団体の資金提供イニシアティブは、この分野の研究開発に重要な財政支援を行っています。消費者の行動も一役買っており、患者は従来の医薬品を超えた代替療法や個別化医療のアプローチをますます支持するようになっています。さらに、獣医学、農業、水産養殖は、抗生物質依存を減らし微生物制御を改善するためにファージベースのソリューションが使用される強力な応用分野として浮上しています。これらすべての要因が、感染症の回復力とヘルスケア・イノベーションに対する世界の関心の高まりと相まって、ファージ療法を、将来性の高い、多分野にまたがる成長分野として位置づけています。

セグメント

製品（大腸菌、黄色ブドウ球菌、サルモネラ菌、その他の製品）;用途（動物用医薬品、食品、その他の用途）

調査対象企業の例

  • Adaptive Phage Therapeutics
  • Armata Pharmaceuticals
  • BiomX Ltd.
  • C3J Therapeutics
  • CYTOBIOTICS Inc.
  • Eligo Bioscience
  • EnBiotix, Inc.
  • InnoPhage Ltd.
  • Intralytix, Inc.
  • Locus Biosciences
  • Micreos Human Health
  • Nextbiotics
  • OmniPhage
  • Phagelux Inc.
  • Pherecydes Pharma
  • Phico Therapeutics Ltd.
  • TechnoPhage SA
  • TAILF Therapeutics
  • The Eliava Foundation
  • VyPhI, Inc.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP37720

Global Phage Therapy Market to Reach US$124.8 Million by 2030

The global market for Phage Therapy estimated at US$45.3 Million in the year 2024, is expected to reach US$124.8 Million by 2030, growing at a CAGR of 18.4% over the analysis period 2024-2030. Escherichia Coli, one of the segments analyzed in the report, is expected to record a 20.4% CAGR and reach US$69.1 Million by the end of the analysis period. Growth in the Staphylococcus Aureus segment is estimated at 15.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$11.9 Million While China is Forecast to Grow at 17.3% CAGR

The Phage Therapy market in the U.S. is estimated at US$11.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$19.1 Million by the year 2030 trailing a CAGR of 17.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 17.2% and 15.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.3% CAGR.

Global Phage Therapy Market - Key Trends & Drivers Summarized

Can Bacteriophages Offer a New Frontier in the Fight Against Antibiotic Resistance?

The escalating global crisis of antibiotic resistance has placed phage therapy under the spotlight as a promising alternative for combating multidrug-resistant bacterial infections. Bacteriophages, or phages, are viruses that selectively infect and destroy bacteria, offering a highly targeted approach without disturbing beneficial microbiota. Unlike traditional antibiotics, which operate on broad-spectrum mechanisms, phages can be tailored to attack specific bacterial strains, thereby minimizing collateral damage and reducing the risk of resistance development. As antibiotic-resistant superbugs continue to threaten public health globally, the appeal of phage therapy is growing not only in clinical medicine but also in sectors like agriculture, aquaculture, and food safety. Multiple countries are now reevaluating regulatory pathways to facilitate the research and clinical integration of phage-based treatments, especially in cases where conventional antibiotics fail. Notably, compassionate use cases and individualized phage therapy have shown life-saving results in critically ill patients, further boosting interest in this technology. Academic institutions, biotech startups, and public health agencies are increasingly collaborating on global phage banks and sequencing libraries to enhance the availability and customization of phage cocktails. The specificity of phage-host interactions, while challenging, also offers a significant advantage in minimizing unintended effects on the broader ecosystem. With infectious disease control facing new hurdles in a post-antibiotic era, phage therapy is being reevaluated not as an experimental outlier but as a strategic pillar in future antimicrobial protocols.

How Is Innovation in Biotechnology Advancing the Clinical Utility of Phage Therapy?

Advancements in genetic engineering, synthetic biology, and bioinformatics are playing a pivotal role in expanding the clinical relevance of phage therapy. Today’s phage research is far more sophisticated than in earlier decades, with scientists now able to modify phages to overcome bacterial defenses, enhance lytic efficiency, and avoid immune system detection. CRISPR-Cas systems are being employed to design programmable phages capable of targeting specific resistance genes, making the therapy adaptable to a wide array of infections. Additionally, innovations in sequencing technologies and metagenomics are accelerating the identification of effective phage-bacteria pairs, significantly reducing the time required for personalized treatment planning. Encapsulation techniques and nanoformulations are also emerging to improve phage stability, bioavailability, and targeted delivery to infected tissues. The development of phage cocktails, which combine multiple phage strains, is enhancing spectrum coverage and mitigating resistance development during treatment. Biotechnology companies are working on scalable production and purification methods that meet GMP standards, addressing one of the major hurdles in bringing phage therapies to market. Clinical trials in Europe, North America, and Asia are increasingly investigating the role of phage therapy in treating infections ranging from chronic wounds to cystic fibrosis-associated pathogens. Such technological momentum is transforming phage therapy from a last-resort option into a versatile and scientifically validated modality. With the continued convergence of high-throughput lab tools and AI-driven screening systems, phage-based therapeutics are gaining credibility as a next-generation weapon in precision medicine.

What Regulatory and Infrastructure Challenges Must Be Addressed for Widespread Adoption?

Despite its potential, the widespread adoption of phage therapy faces numerous regulatory and infrastructural barriers that need urgent attention. Traditional drug approval frameworks are not well-suited to therapies that require high personalization, such as phage preparations that must be matched to a patient’s specific bacterial infection. This lack of regulatory clarity slows clinical development and discourages large-scale investment. Regulatory agencies like the FDA and EMA are gradually exploring adaptive licensing models, including compassionate use and hospital exemptions, but uniform global standards remain elusive. Manufacturing consistency, quality control, and phage characterization present additional challenges, as these biologics must be free of contaminants, genetically stable, and functionally reproducible. Another hurdle lies in the current lack of commercial-scale phage production facilities equipped to meet medical-grade standards. Many institutions still rely on in-house labs or academic setups, which limits output and quality standardization. Additionally, the scarcity of clinical professionals trained in phage therapy impedes its routine adoption in hospitals. Public perception and awareness also lag behind scientific advances, with many still viewing phage therapy as experimental or unconventional. Intellectual property constraints further complicate commercialization, as naturally occurring phages are difficult to patent, reducing the incentive for private sector investment. Cross-border collaborations and global consortia are beginning to address these gaps, but the need for dedicated policies, infrastructure upgrades, and industry-wide education remains critical. Overcoming these regulatory and logistical hurdles is essential to fully unlock the global potential of phage therapy as a mainstream medical tool.

What Forces Are Fueling Market Growth and Expanding Therapeutic Applications?

The growth in the phage therapy market is driven by several factors related to technological progress, unmet clinical needs, and evolving patient care models. One of the most significant drivers is the surge in multidrug-resistant infections, which are rendering conventional antibiotics increasingly ineffective and heightening demand for viable alternatives. Simultaneously, the advancement of genomic and proteomic tools has dramatically improved phage identification, customization, and deployment, thereby reducing developmental timelines and boosting therapeutic efficacy. The increasing incidence of chronic and hospital-acquired infections is also fueling demand for targeted antimicrobials that can circumvent traditional resistance mechanisms. On the end-user side, hospitals and specialized infection clinics are beginning to incorporate phage therapy for difficult-to-treat cases, supported by growing evidence from pilot programs and case studies. Biopharmaceutical companies and academic research centers are investing heavily in the creation of phage libraries, predictive modeling software, and scalable manufacturing systems to broaden therapeutic availability. Government and non-profit funding initiatives focused on combating antibiotic resistance are providing critical financial support for R&D in this space. Consumer behavior is also playing a role, with patients increasingly advocating for alternative therapies and personalized medicine approaches that go beyond traditional pharmaceuticals. Additionally, veterinary medicine, agriculture, and aquaculture are emerging as strong application areas where phage-based solutions are being used to reduce antibiotic dependency and improve microbial control. All these factors, combined with an intensifying global focus on infectious disease resilience and healthcare innovation, are positioning phage therapy as a high-potential, multidisciplinary growth sector for the foreseeable future.

SCOPE OF STUDY:

The report analyzes the Phage Therapy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Escherichia Coli, Staphylococcus Aureus, Salmonella, Other Products); Application (Animal Health Application, Food Application, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 47 Featured) -

  • Adaptive Phage Therapeutics
  • Armata Pharmaceuticals
  • BiomX Ltd.
  • C3J Therapeutics
  • CYTOBIOTICS Inc.
  • Eligo Bioscience
  • EnBiotix, Inc.
  • InnoPhage Ltd.
  • Intralytix, Inc.
  • Locus Biosciences
  • Micreos Human Health
  • Nextbiotics
  • OmniPhage
  • Phagelux Inc.
  • Pherecydes Pharma
  • Phico Therapeutics Ltd.
  • TechnoPhage SA
  • TAILF Therapeutics
  • The Eliava Foundation
  • VyPhI, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Phage Therapy - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Threat of Antibiotic Resistance Propels Demand for Alternative Antibacterial Therapies
    • Growing Clinical Validation of Phage Therapy Strengthens the Business Case for Targeted Bacteriophage Solutions
    • Increased Investment in Precision Medicine Expands the Addressable Market for Customized Phage Treatments
    • Regulatory Pathway Reforms and Compassionate Use Programs Throw the Spotlight on Phage-Based Therapeutics
    • Advancements in Genomic Sequencing and Synthetic Biology Drive Innovation in Next-Generation Phage Platforms
    • Outbreaks of Multidrug-Resistant Infections Accelerate Interest in Emergency and Hospital-Based Phage Applications
    • Establishment of Phage Banks and Libraries Supports Scalable, On-Demand Therapeutic Development
    • Integration with AI and Machine Learning Enables Faster Identification and Matching of Phages to Pathogens
    • Growing Acceptance of Microbiome Modulation Throws the Spotlight on Phages as Precision Modifiers
    • Expansion of Phage Therapy Trials Beyond Infectious Diseases Generates Opportunities in Oncology and Dermatology
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Phage Therapy Market Analysis of Annual Sales in US$ for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Phage Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Phage Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Escherichia Coli by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Escherichia Coli by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Staphylococcus Aureus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Staphylococcus Aureus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Salmonella by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Salmonella by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Animal Health Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Animal Health Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Food Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Food Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Phage Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 18: USA Recent Past, Current & Future Analysis for Phage Therapy by Product - Escherichia Coli, Staphylococcus Aureus, Salmonella and Other Products - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 19: USA 6-Year Perspective for Phage Therapy by Product - Percentage Breakdown of Value Sales for Escherichia Coli, Staphylococcus Aureus, Salmonella and Other Products for the Years 2025 & 2030
    • TABLE 20: USA Recent Past, Current & Future Analysis for Phage Therapy by Application - Animal Health Application, Food Application and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA 6-Year Perspective for Phage Therapy by Application - Percentage Breakdown of Value Sales for Animal Health Application, Food Application and Other Applications for the Years 2025 & 2030
  • CANADA
    • TABLE 22: Canada Recent Past, Current & Future Analysis for Phage Therapy by Product - Escherichia Coli, Staphylococcus Aureus, Salmonella and Other Products - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 23: Canada 6-Year Perspective for Phage Therapy by Product - Percentage Breakdown of Value Sales for Escherichia Coli, Staphylococcus Aureus, Salmonella and Other Products for the Years 2025 & 2030
    • TABLE 24: Canada Recent Past, Current & Future Analysis for Phage Therapy by Application - Animal Health Application, Food Application and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 25: Canada 6-Year Perspective for Phage Therapy by Application - Percentage Breakdown of Value Sales for Animal Health Application, Food Application and Other Applications for the Years 2025 & 2030
  • JAPAN
    • Phage Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 26: Japan Recent Past, Current & Future Analysis for Phage Therapy by Product - Escherichia Coli, Staphylococcus Aureus, Salmonella and Other Products - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Japan 6-Year Perspective for Phage Therapy by Product - Percentage Breakdown of Value Sales for Escherichia Coli, Staphylococcus Aureus, Salmonella and Other Products for the Years 2025 & 2030
    • TABLE 28: Japan Recent Past, Current & Future Analysis for Phage Therapy by Application - Animal Health Application, Food Application and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 29: Japan 6-Year Perspective for Phage Therapy by Application - Percentage Breakdown of Value Sales for Animal Health Application, Food Application and Other Applications for the Years 2025 & 2030
  • CHINA
    • Phage Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 30: China Recent Past, Current & Future Analysis for Phage Therapy by Product - Escherichia Coli, Staphylococcus Aureus, Salmonella and Other Products - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 31: China 6-Year Perspective for Phage Therapy by Product - Percentage Breakdown of Value Sales for Escherichia Coli, Staphylococcus Aureus, Salmonella and Other Products for the Years 2025 & 2030
    • TABLE 32: China Recent Past, Current & Future Analysis for Phage Therapy by Application - Animal Health Application, Food Application and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 33: China 6-Year Perspective for Phage Therapy by Application - Percentage Breakdown of Value Sales for Animal Health Application, Food Application and Other Applications for the Years 2025 & 2030
  • EUROPE
    • Phage Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 34: Europe Recent Past, Current & Future Analysis for Phage Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 35: Europe 6-Year Perspective for Phage Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 36: Europe Recent Past, Current & Future Analysis for Phage Therapy by Product - Escherichia Coli, Staphylococcus Aureus, Salmonella and Other Products - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Europe 6-Year Perspective for Phage Therapy by Product - Percentage Breakdown of Value Sales for Escherichia Coli, Staphylococcus Aureus, Salmonella and Other Products for the Years 2025 & 2030
    • TABLE 38: Europe Recent Past, Current & Future Analysis for Phage Therapy by Application - Animal Health Application, Food Application and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Europe 6-Year Perspective for Phage Therapy by Application - Percentage Breakdown of Value Sales for Animal Health Application, Food Application and Other Applications for the Years 2025 & 2030
  • FRANCE
    • Phage Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 40: France Recent Past, Current & Future Analysis for Phage Therapy by Product - Escherichia Coli, Staphylococcus Aureus, Salmonella and Other Products - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 41: France 6-Year Perspective for Phage Therapy by Product - Percentage Breakdown of Value Sales for Escherichia Coli, Staphylococcus Aureus, Salmonella and Other Products for the Years 2025 & 2030
    • TABLE 42: France Recent Past, Current & Future Analysis for Phage Therapy by Application - Animal Health Application, Food Application and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 43: France 6-Year Perspective for Phage Therapy by Application - Percentage Breakdown of Value Sales for Animal Health Application, Food Application and Other Applications for the Years 2025 & 2030
  • GERMANY
    • Phage Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 44: Germany Recent Past, Current & Future Analysis for Phage Therapy by Product - Escherichia Coli, Staphylococcus Aureus, Salmonella and Other Products - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Germany 6-Year Perspective for Phage Therapy by Product - Percentage Breakdown of Value Sales for Escherichia Coli, Staphylococcus Aureus, Salmonella and Other Products for the Years 2025 & 2030
    • TABLE 46: Germany Recent Past, Current & Future Analysis for Phage Therapy by Application - Animal Health Application, Food Application and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Germany 6-Year Perspective for Phage Therapy by Application - Percentage Breakdown of Value Sales for Animal Health Application, Food Application and Other Applications for the Years 2025 & 2030
  • ITALY
    • TABLE 48: Italy Recent Past, Current & Future Analysis for Phage Therapy by Product - Escherichia Coli, Staphylococcus Aureus, Salmonella and Other Products - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Italy 6-Year Perspective for Phage Therapy by Product - Percentage Breakdown of Value Sales for Escherichia Coli, Staphylococcus Aureus, Salmonella and Other Products for the Years 2025 & 2030
    • TABLE 50: Italy Recent Past, Current & Future Analysis for Phage Therapy by Application - Animal Health Application, Food Application and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Italy 6-Year Perspective for Phage Therapy by Application - Percentage Breakdown of Value Sales for Animal Health Application, Food Application and Other Applications for the Years 2025 & 2030
  • UNITED KINGDOM
    • Phage Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 52: UK Recent Past, Current & Future Analysis for Phage Therapy by Product - Escherichia Coli, Staphylococcus Aureus, Salmonella and Other Products - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 53: UK 6-Year Perspective for Phage Therapy by Product - Percentage Breakdown of Value Sales for Escherichia Coli, Staphylococcus Aureus, Salmonella and Other Products for the Years 2025 & 2030
    • TABLE 54: UK Recent Past, Current & Future Analysis for Phage Therapy by Application - Animal Health Application, Food Application and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 55: UK 6-Year Perspective for Phage Therapy by Application - Percentage Breakdown of Value Sales for Animal Health Application, Food Application and Other Applications for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Phage Therapy by Product - Escherichia Coli, Staphylococcus Aureus, Salmonella and Other Products - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Rest of Europe 6-Year Perspective for Phage Therapy by Product - Percentage Breakdown of Value Sales for Escherichia Coli, Staphylococcus Aureus, Salmonella and Other Products for the Years 2025 & 2030
    • TABLE 58: Rest of Europe Recent Past, Current & Future Analysis for Phage Therapy by Application - Animal Health Application, Food Application and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Rest of Europe 6-Year Perspective for Phage Therapy by Application - Percentage Breakdown of Value Sales for Animal Health Application, Food Application and Other Applications for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Phage Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 60: Asia-Pacific Recent Past, Current & Future Analysis for Phage Therapy by Product - Escherichia Coli, Staphylococcus Aureus, Salmonella and Other Products - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Asia-Pacific 6-Year Perspective for Phage Therapy by Product - Percentage Breakdown of Value Sales for Escherichia Coli, Staphylococcus Aureus, Salmonella and Other Products for the Years 2025 & 2030
    • TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Phage Therapy by Application - Animal Health Application, Food Application and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Asia-Pacific 6-Year Perspective for Phage Therapy by Application - Percentage Breakdown of Value Sales for Animal Health Application, Food Application and Other Applications for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 64: Rest of World Recent Past, Current & Future Analysis for Phage Therapy by Product - Escherichia Coli, Staphylococcus Aureus, Salmonella and Other Products - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Rest of World 6-Year Perspective for Phage Therapy by Product - Percentage Breakdown of Value Sales for Escherichia Coli, Staphylococcus Aureus, Salmonella and Other Products for the Years 2025 & 2030
    • TABLE 66: Rest of World Recent Past, Current & Future Analysis for Phage Therapy by Application - Animal Health Application, Food Application and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Rest of World 6-Year Perspective for Phage Therapy by Application - Percentage Breakdown of Value Sales for Animal Health Application, Food Application and Other Applications for the Years 2025 & 2030

IV. COMPETITION